HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy.

Abstract
Glutamic acid decarboxylase antibodies (GAD-abs) are an immunological factor involved in type 1 diabetes and other diseases involving the central nervous system. This report is of a patient with type 1 diabetes and a rare case of non-paraneoplastic limbic encephalitis mediated by anti-GAD65 antibodies that improved with the use of immunosuppressive drugs.
AuthorsM Lopez-Sublet, H Bihan, G Reach, S Dupont, A Didelot, J-J Mourad, A Krivitzky, R Dhote
JournalDiabetes & metabolism (Diabetes Metab) Vol. 38 Issue 3 Pg. 273-5 (Jun 2012) ISSN: 1878-1780 [Electronic] France
PMID22463975 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2012 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Glutamate Decarboxylase
  • glutamate decarboxylase 2
Topics
  • Adult
  • Autoimmunity
  • Diabetes Mellitus, Type 1 (complications, drug therapy, immunology)
  • Female
  • Glutamate Decarboxylase (immunology)
  • Humans
  • Immunization, Passive (methods)
  • Immunoglobulins, Intravenous (administration & dosage)
  • Immunosuppressive Agents (therapeutic use)
  • Limbic Encephalitis (drug therapy, immunology)
  • Magnetic Resonance Imaging
  • Neuropsychological Tests
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: